This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat
by Zacks Equity Research
Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA
by Kinjel Shah
Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) release Q3 results. FDA approves Glaxo's (GSK) Zejula and AstraZeneca's Farxiga for more patients. CHMP gives nod to several drugs
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.
Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
by Zacks Equity Research
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Roche Posts Solid Sales for First 9 Months of '19, Ups View
by Zacks Equity Research
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
Roche Announces Positive Late-Stage Data on Rituxan in PV
by Zacks Equity Research
Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
by Ekta Bagri
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval
by Zacks Equity Research
Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.
Is Novartis (NVS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
by Zacks Equity Research
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
by Zacks Equity Research
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx
by Zacks Equity Research
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
by Kinjel Shah
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
by Zacks Equity Research
Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali
by Zacks Equity Research
Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.